Dr. Schwartz on Results From the GIST Cohort in the Alliance A091401 Trial

Video

In Partnership With:

Gary K. Schwartz, MD, discusses the results from the gastrointestinal stromal tumor cohort of the phase 2 Alliance A091401 trial.

Gary K. Schwartz, MD, professor of medicine, chief, Division of Hematology​/Oncology, ​deputy director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, discusses the results from the gastrointestinal stromal tumor (GIST) cohort of the phase 2 Alliance A091401 trial.

In the Alliance A091401 trial, patients with advanced sarcoma were randomized to receive nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy).

In the United States, GIST is a common sarcoma ​subtype, ​and finding new therapies is of critical importance​, says Schwartz.

Until the GIST cohort was added to the trial, it was unknown whether patients with GIST could benefit from immunotherapy, Schwartz explains.

However, no patients in the GIST cohort achieved a partial or complete response with either the single agent or combination regimen, and the trial was stopped ​early due to increased treatment-related adverse effects, Schwartz concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD